LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Studied

Discovery research assessed LY3437943, later known as retatrutide, a peptide activating glucagon, GIP and GLP-1 receptors, through laboratory experiments, obese-mouse studies and an early phase 1 single-dose study.

Who / model

The abstract describes obese mice and a phase 1 study but does not report sample sizes, participant characteristics or comparators.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

In mice, treatment reduced weight and improved glucose control, with increased energy expenditure and reduced calorie intake. In phase 1, weight reduction persisted to day 43 after one dose; the reported safety and tolerability profile resembled other incretins.

Limits

Authors called for further clinical assessment. The mouse mechanism does not establish the same mechanism or effectiveness in humans; the abstract provides no detailed adverse-event counts.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary